NeoPharm Ownership

092730 Stock  KRW 12,000  90.00  0.74%   
The market capitalization of NeoPharm LTD is W156.02 Billion. NeoPharm LTD holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the firm is less than the current market value, you may not be able generate positive returns on investment in the long run.
Some institutional investors establish a significant position in stocks such as NeoPharm in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of NeoPharm, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in NeoPharm LTD. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

NeoPharm Stock Ownership Analysis

About 39.0% of the company shares are owned by insiders or employees . The company recorded earning per share (EPS) of 576.0. NeoPharm LTD had not issued any dividends in recent years. The entity had 1:2 split on the 18th of September 2024. ,Ltd. manufactures and sells skin care products in Korea and internationally. ,Ltd. was founded in 2000 and is headquartered in Daejeon, South Korea. Neopharm is traded on Korean Securities Dealers Automated Quotations in South Korea. For more info on NeoPharm LTD please contact the company at 82 4 2863 0038 or go to https://www.neopharm.co.kr.

NeoPharm Outstanding Bonds

NeoPharm issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. NeoPharm LTD uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most NeoPharm bonds can be classified according to their maturity, which is the date when NeoPharm LTD has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Other Information on Investing in NeoPharm Stock

NeoPharm financial ratios help investors to determine whether NeoPharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NeoPharm with respect to the benefits of owning NeoPharm security.